Prognosis of thymectomy in myasthenia gravis patients with thymus hyperplasia

Abstract Purpose: To compare the post-thymectomy prognosis in different conditions of myasthenia gravis (MG) patients with thymus hyperplasia. Materials and methods: Collecting medical record and carrying out the follow-up study of 123 myasthenia gravis patients with thymus hyperplasia who have underwent thymectomy during the period between 2003 and 2013. Dividing into different groups based on gender, age of onset, duration of disease and Myasthenia Gravis Association of America (MGFA) clinical classification to analyze different prognosis in different groups. Results: Complete stable remission (CSR) was achieved in 71 of 123 patients (59.5%). There is no gender-related difference in achieving CSR. Patients with early onset of MG (≤40 years old) or disease duration less than 12 months had significantly higher CSR rates than those with late onset of MG (>40 years old) or disease duration more than 12 months respectively, while no difference was found in remission rate between MGFA clinical classification I and MGFA II. Conclusion: Myasthenia gravis patients with thymus hyperplasia who had thymectomy are proved to possess greater chance of achieving CSR. The onset age of disease and duration are the prognostic factors.

[1]  G. Cutter,et al.  Randomized trial of thymectomy in myasthenia gravis. , 2016, Journal of thoracic disease.

[2]  I. Yoshino,et al.  Two-year outcome of thymectomy in non-thymomatous late-onset myasthenia gravis , 2015, Journal of Neurology.

[3]  Ariel Miller,et al.  Genetic basis of myasthenia gravis - a comprehensive review. , 2014, Journal of autoimmunity.

[4]  S. Berrih-Aknin,et al.  Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms. , 2014, Journal of autoimmunity.

[5]  J. Sieb Myasthenia gravis: an update for the clinician , 2014, Clinical and experimental immunology.

[6]  J. Dunning,et al.  Is thymectomy in non-thymomatous myasthenia gravis of any benefit? , 2014, Interactive cardiovascular and thoracic surgery.

[7]  K. Levin,et al.  Myasthenia gravis: Newer therapies offer sustained improvement , 2013, Cleveland Clinic Journal of Medicine.

[8]  M. Hayward,et al.  Thymectomy: role in the treatment of myasthenia gravis , 2013, Journal of Neurology.

[9]  J. Vajsar,et al.  Efficacy and safety of thoracoscopic thymectomy in the treatment of juvenile myasthenia gravis , 2013, Pediatric Surgery International.

[10]  V. Herlea,et al.  Ten-Year Results of Thoracoscopic Unilateral Extended Thymectomy Performed in Nonthymomatous Myasthenia Gravis , 2011, Annals of surgery.

[11]  J. Izbicki,et al.  Long-term outcome and quality of life after open and thoracoscopic thymectomy for myasthenia gravis: analysis of 131 patients , 2008, Surgical Endoscopy.

[12]  K. Arimura,et al.  Effects of thymectomy on late-onset myasthenia gravis without thymoma , 2007, Clinical Neurology and Neurosurgery.

[13]  W. Hsu,et al.  Factors influencing the outcome of transsternal thymectomy for myasthenia gravis , 2005, Acta neurologica Scandinavica.

[14]  Y. Monden,et al.  Extended thymectomy for myasthenia gravis patients: a 20-year review. , 1996, The Annals of thoracic surgery.

[15]  D. Elmqvist Myasthenia Gravis , 1975, The Lancet.